Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 18.61 M

Nyxoah S.A. Net Cash Used Provided By Financing Activities is USD 18.61 M for the year ending December 31, 2023, a 1,869.15% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Nyxoah S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -1.05 M, a -101.21% change year over year.
Nyxoah S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 87.05 M, a -31.59% change year over year.
Nyxoah S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 127.26 M, a 15,370.35% change year over year.
Nyxoah S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 822.59 K, a -95.21% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Dental Care Medical Instruments Pharmaceuticals Pollution Treatment Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years